Neurocrine BiosciencesNBIX

那斯達克 · USD
163.88
-3.47
(-2.07%)
收盤 06/06 03:59 (UTC+8)
06/06 03:59 (UTC+8)

財務數據

損益表

loading
載入中...
icon
  • 5.15
  • 5.15
  • 5.90
  • 6.22
  • 6.28
  • 5.73
  • 6.88
  • 7.95
  • 8.06
  • 8.15
icon
  • 3.29
  • 0.02
  • 14.54
  • 5.40
  • 0.90
  • -8.78
  • 20.07
  • 15.62
  • 1.33
  • 1.12
  • icon
    營業收入(億)
  • icon
    季增長率(%)
單位:美元千元
年季
2026/Q1
2025/Q4
2025/Q3
2025/Q2
2025/Q1
2024/Q4
2024/Q3
2024/Q2
2024/Q1
2023/Q4
營業收入淨額
814,500
805,500
794,900
687,500
572,600
627,700
622,100
590,200
515,300
515,200
營業成本
13,80017,60014,00011,3009,2009,3008,0009,2007,5008,500
營業毛利
800,700
787,900
780,900
676,200
563,400
618,400
614,100
581,000
507,800
506,700
營業費用
635,900577,000541,900530,600539,800476,400430,300-408,500356,400
研發費用
296,200258,200250,000244,300263,200185,600195,000191,100159,400137,500
推銷及管理費用
318,500301,800291,600286,300276,500287,800234,300242,000243,100218,900
非經常性項目費用
21,20017,000300-1003,0001,0002,5006,000-
其他營業費用
----------
營業利益
186,000
210,900
239,000
145,600
23,600
142,000
183,800
145,400
99,300
150,300
其他收入及費用
56,70025,80022,20020,60021,70022,50023,400-26,900-65,30023,500
利息費用
--------1,1004,600
稅前純益
246,800
239,400
291,800
159,500
14,700
162,600
190,300
98,600
34,500
198,200
所得稅
48,90085,70082,30052,0006,80059,50060,50033,600-8,90050,500
稅後純益
197,900
153,700
209,500
107,500
7,900
103,100
129,800
65,000
43,400
147,700
基本每股稅後盈餘(元)
1.971.542.111.090.081.031.280.640.431.50
稀釋每股稅後盈餘(元)
1.911.482.061.050.081.001.250.620.421.46
基本平均股數(千股)
100500.0099900.0099400.0099000.0099700.00100000.00101100.00100800.0099800.0098400.00
稀釋平均股數(千股)
103400.00103700.00102500.00101000.00102500.00102900.00104300.00103900.00103600.00102300.00
還原基本每股稅後盈餘(元)
1.971.542.111.090.081.031.280.640.431.50
還原稀釋每股稅後盈餘(元)
1.911.482.061.050.081.001.250.620.421.46
還原基本平均股數(千股)
100,50099,90099,40099,00099,700100,000101,100100,80099,80098,400
還原稀釋平均股數(千股)
103,400103,700102,500101,000102,500102,900104,300103,900103,600102,300
EBITDA(千元)
252,800244,900296,800163,40017,700164,100190,30098,90034,700202,900

大家都在看

HOT